Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people
05:30am, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Avril 2022
05:48pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc
Sanofi: Information concerning the total number of voting rights and shares – April 2022
05:48pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Is Banco Santander (SAN) Stock Undervalued Right Now?
01:40pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Is Banco Santander (SAN) Stock Undervalued Right Now?
11:18am, Thursday, 02'nd Jun 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A
05:00am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A
Communiqué de presse: La FDA accorde la désignation de « Traitement innovant » à l’efanesoctocog alpha pour le traitement de l’hémophilie A
05:00am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
La FDA accorde la désignation de « Traitement innovant » à l’efanesoctocog alpha pour le traitement de l’hémophilie A
Zacks Industry Outlook Highlights UBS Group AG, Banco Santander S.A., and Bancolombia S.A
01:06pm, Tuesday, 31'st May 2022 Zacks Investment Research
UBS Group AG, Banco Santander S.A., and Bancolombia S.A are part of Zacks Industry Outlook article.
Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
05:00am, Tuesday, 31'st May 2022 GlobeNewswire Inc.
FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
Communiqué de presse: La FDA accorde un examen prioritaire à Dupixent® (dupilumab) dans le traitement du prurigo nodulaire de l’adulte
05:00am, Tuesday, 31'st May 2022 GlobeNewswire Inc.
La FDA accorde un examen prioritaire à Dupixent® (dupilumab) dans le traitement du prurigo nodulaire de l’adulte
Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial
05:30am, Monday, 30'th May 2022 GlobeNewswire Inc.
Update on Cialis® Rx-to-OTC Switch Actual Use Trial
Communiqué de presse: Point sur l’essai en condition réelle d’utilisation de Cialis® en vue de son transfert sur le marché de l'automédication
05:30am, Monday, 30'th May 2022 GlobeNewswire Inc.
Point sur l’essai en condition réelle d’utilisation de Cialis® en vue de son transfert sur le marché de l'automédication
3 Top Stocks to Buy From the Prospering Foreign Banks Industry
12:21pm, Friday, 27'th May 2022 Zacks Investment Research
Despite concerns related to higher restructuring costs and uneven economic growth, Zacks Foreign Banks industry stocks like UBS, Banco Santander (SAN) and Bancolombia (CIB) are poised to gain from int
3 Top Stocks to Buy From the Prospering Foreign Banks Industry
09:48am, Friday, 27'th May 2022
Despite concerns related to higher restructuring costs and uneven economic growth, Zacks Foreign Banks industry stocks like UBS, Banco Santander (SAN) and Bancolombia (CIB) are poised to gain from int
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
07:15pm, Friday, 20'th May 2022 GlobeNewswire Inc.
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
